RECRUITING

Cerebellum and Autism: Regional Specialization for Social and Executive Functions

Talk to us

Conditions

AutismAutism Spectrum Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to determine the impact of neuromodulation to the cerebellum on social and executive functions in neurotypical young adults and young adults with autism.

Official Title

Cerebellum and Autism: Regional Specialization for Social and Executive Functions

Quick Facts

Study Start:2022-01-01
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05396352

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged 18-35
  2. * Able to provide written, informed consent
  3. * NIH Toolbox age-adjusted Cognitive Function Composite standard score ≥ 85
  4. * Native English speaker
  5. * Right-handed
  6. * Not pregnant
  7. * Able to attend all study sessions
  8. * Pass safety screening for MRI and neuromodulation (e.g. no metal in body, implanted devices, history of seizure, claustrophobia)
  9. * Prior research-reliable diagnosis of autism spectrum disorder (ASD) Or
  10. * Meet DSM-5 criteria for ASD confirmed with ADOS-2 via research-reliable clinical assessment
  1. * Age \<18 or \>35
  2. * NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85
  3. * Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)
  4. * Current or prior history of neurological or neurodevelopmental condition or brain injury
  5. * Psychotropic medication
  6. * Pregnancy
  7. * Age \<18 or \>35
  8. * Participants with a legal authorized representative
  9. * NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85
  10. * Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)
  11. * Pregnancy

Contacts and Locations

Study Contact

Catherine Stoodley, D.Phil.
CONTACT
202-885-1785
stoodley@american.edu

Principal Investigator

Catherine Stoodley, D.Phil.
PRINCIPAL_INVESTIGATOR
American University

Study Locations (Sites)

American University
Washington, District of Columbia, 20016
United States

Collaborators and Investigators

Sponsor: American University

  • Catherine Stoodley, D.Phil., PRINCIPAL_INVESTIGATOR, American University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-01-01
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2022-01-01
Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Autism
  • Autism Spectrum Disorder